CompletedPHASE2, PHASE3NCT01315795

Lanreotide Autogel in the Treatment of Symptomatic Polycystic Liver Disease

Studying Isolated polycystic liver disease

Last synced from ClinicalTrials.gov May 11, 2026

ℹ

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.

Report missing data

Key facts

Sponsor: Universitaire Ziekenhuizen KU Leuven
Principal Investigator: Frederik Nevens, MD, PhD
UZ Leuven, Gasthuisberg
Intervention: Lanreotide Autogel 90 mg and 120 mg(drug)
Enrollment: 59 enrolled
Eligibility: 18 years · All sexes
Timeline: 2011 – 2014

Study locations (1)

UZ Leuven, Gasthuisberg, Leuven, Provincie Vlaams-Brabant, Belgium

Collaborators

Ipsen

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT01315795 on ClinicalTrials.gov

Other trials for Isolated polycystic liver disease

Additional recruiting or active studies for the same condition.

RECRUITINGNCT04645251
Polycystic Liver Disease Registry (UK)
Portsmouth Hospitals NHS Trust

See all trials for Isolated polycystic liver disease →

← Back to all trials